Main Inclusion Criteria:

          1. Relapsed or refractory disease and previously treated with at least 1 line of systemic
             antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy
             since lymphoma diagnosis

          2. One of the confirmed histologies below with CD20-positivity:

               1. DLBCL, NOS, including de novo or histologically transformed from FL

               2. "Double-hit" or "triple-hit" DLBCL (technically classified in WHO 2016 as HGBCL,
                  with MYC and BCL2 and/or BCL6 translocations), including de novo or
                  histologically transformed from FL

               3. FL Grade 3B

          3. ECOG PS score of 0-2

          4. Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening

          5. Patients must have detectable disease by PET scan and measurable by CT scan or MRI

          6. Acceptable renal and liver function

          7. Life expectancy >2 months on SOC treatment

        Main Exclusion Criteria:

          1. Primary CNS tumor or known CNS involvement

          2. Any prior therapy with a bispecific antibody targeting CD3 and CD20

          3. Major surgery within 4 weeks prior to randomization

          4. Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs)
             within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization

          5. Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to
             randomization

          6. ASCT within 100 days of randomization

          7. Treatment with CAR-T therapy within 100 days prior to randomization

          8. Seizure disorder requiring anti-epileptic therapy

          9. Clinically significant cardiac disease,